Browse by category

A scoping review by researchers from the US and Mexico have reported that although one anastomosis gastric bypass (OAGB) is an effective metabolic and bariatric procedure with favourable outcomes in weight loss and disease remission, heterogeneity in surgical techniques, outcome definitions, and limited follow-up time to assess long-term outcomes, emphasise the need for standardised reporting and further high-quality long-term studies to guide patient selection and decision m

Researchers from the US have reported continual postoperative monitoring of boredom and stress, particularly two to three years after surgery, could help prevent loss of control eating (LOCE) after metabolic and bariatric surgery (MBS), and thus support the long-term psychosocial wellbeing of patients after MBS. Loss of control eating is defined as the subjective experience of loss of control while eating regardless of the amount of food consumed and has emerged as a salient

Fasting completion rates during Ramadan are significantly influenced by the time elapsed since surgery, with patients who underwent laparoscopic sleeve gastrectomy (LSG) 12 months or more before Ramadan having the highest success rates, according to researchers from Benha University, Benha and Tanta University, Tanta, Egypt. In addition, prior fasting experiences positively impacted fasting completion rates. The study authors stated that fasting during Ramadan presents unique

Intraparietal gastric botulinum toxin-A injection (Botox) can lead to significant weight loss and may contribute to the development of effective, minimally-invasive approaches for the management of obesity, according to researchers from Turkey. However, they noted that further studies with larger sample sizes and longer follow-up periods are needed to confirm these findings. This study investigated the effects of intragastric botulinum toxin-A injection on weight loss and to

The first meta-analysis to analyse objective oesophageal function data comparing pre- and post- laparoscopic vertical sleeve gastrectomy (LVSG), has conclusively demonstrated the detrimental effect of LVSG on lower esophageal sphincter pressure (LESP) and DeMeester Score (DMS) post-surgery despite significant loss of BMI, researchers from the University of Southern Queensland, Toowoomba, Queensland, Australia. Research has shown that LVSG leads to anatomical changes at the es

Medtimo, a wholly owned subsidiary of Biorad Medisys Private Limited, has filed a patent infringement complaint in the US District Court of the District of Delaware against Allurion Technologies. Medtimo’s complaint claims Allurion's gastric balloon system infringes upon Medtimo's intellectual property. This definitive action follows Allurion’s recent unsuccessful challenge of Medtimo’s patent rights in the US Patent and Trademark Office (USPTO). The complaint alleges that Al

The first peer-reviewed study on the consecutive use of the Allurion’s Smart Capsule, a first of its kind, swallowable, procedure-less weight-loss device, has revealed the multi-centre, retrospective outcomes demonstrated that two consecutive treatments can achieve average total body weight loss of 22.1% (19.3 kg), results comparable to bariatric surgery and high-dose GLP-1 therapy. The Allurion Smart Capsule is designed to be swallowed during a brief outpatient visit, filled

Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). EFX is currently in phase 3 development for the treatment of patient

There have been reports that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may also have the potential to treat alcohol and drug...

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, according to research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25). GLP-1 receptor agonists are now widely prescribed for individuals with type 2 diabetes and weight loss, with a 700% increase in usage reported in the US between 2019 and 2023. These medications alter glucose metabolism, gastric motility and sympathetic to